Lion Biotechnologies Inc: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
Provider: ValuEngine, Inc.
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Lion Biotechnologies Inc Provides Update On Phase II Results For Metastatic Melanoma
Lion Biotechnologies Inc announced that it is providing updated results from a Phase II trial for metastatic melanoma conducted by the National Cancer Institute (NCI) utilizing the tumor-infiltrating lymphocyte (TIL) technology currently licensed by the Company and being developed under a Cooperative Research and Development Agreement (CRADA) with the NCI. Steven A. Rosenberg, M.D., Ph.D., Chief of the NCI Surgery Branch, is the Principal Investigator on this study. The single-site trial included 93 patients in three cohorts. The long-term follow-up data reported by the NCI show an Objective Response (OR) rate of 49% for patients treated with TILs alone. Objective Response is Partial Response (PR) plus Complete Response (CR), with Partial Response defined as a reduction in tumor volume of greater than 50%. Of the 43 patients in this cohort, 12% showed Complete Response, and these patients continue to live more than seven years following treatment, with no measurable disease. Two additional cohorts of 25 patients each were treated with a combination of TILs and Total Body Irradiation (TBI). The cohort receiving TILs and 200 Gy TBI showed a 52% OR and 20% CR; the patients in the latter group continue to live more than seven years following treatment, with no measurable disease.
Latest Developments for Lion Biotechnologies Inc
- Lion Biotechnologies names Elma Hawkins president
- Lion Biotechnologies' lead program with National Cancer Institute demonstrates positive results in patients with Stage 4 Metastatic Melanoma
- Lion Biotechnologies Inc Raises Approximately $23 Million In Private Financing
- Genesis Biopharma Inc Announces Management Change-Form 8-K
Latest Key Developments in Biotechnology
- Share this
- Digg this